Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 studyAntoîne Italiano, Vincent Ribrag, Jean‐Charles Soria et al.|The Lancet Oncology|2018Cited by 614
MEK inhibitors: The chemistry and biological activity of U0126, its analogs, and cyclization productsJohn V. Duncia, Richard E. Olson, Joseph B. Santella et al.|Bioorganic & Medicinal Chemistry Letters|1998Cited by 406
Targeting epigenetic regulators for cancer therapySusan Wee, Liang Schweizer, Stephen B. Baylin et al.|Annals of the New York Academy of Sciences|2014Cited by 80